|
Study Group
|
No.
|
11
|
12
|
22
|
12 + 22
|
|---|
| | |
n (%)
|
n (%)
|
n (%)
|
n (%)
|
p valuea
|
ORb (95% CI)
|
|---|
|
Control
|
256
|
112 (43.8)
|
115 (44.9)
|
29 (11.3)
|
144 (56.2)
| | |
|
All Breast Cancer
|
352
|
164 (46.6)
|
150 (42.6)
|
38 (10.8)
|
188 (53.4)
|
0.51
|
0.89 (0.64–1.23)
|
|
Diagnosis ≤ 40 years
|
203
|
104 (51.2)
|
79 (38.9)
|
20 (9.9)
|
99 (48.8)
|
0.13
|
0.74 (0.51–1.07
|
|
Family History
|
105
|
39 (37.1)
|
53 (50.5)
|
13 (12.4)
|
66 (62.9)
|
0.29
|
1.32 (0.83–2.10)
|
|
Bilateral Disease
|
44
|
21 (47.7)
|
18 (40.9)
|
5 (11.4)
|
23 (52.3)
|
0.63
|
0.85 (0.45–1.62)
|
|
All Ovarian Tumours
|
390
|
202 (51.8)
|
153 (39.2)
|
35 (9.0)
|
188 (48.2)
|
0.05
|
0.72 (0.53–0.99)
|
|
All Malignant
|
313
|
157 (50.2)
|
126 (40.2)
|
30 (9.6)
|
156 (49.8)
|
0.13
|
0.77 (0.55–1.08)
|
|
Serous
|
127
|
62 (48.8)
|
52 (40.9)
|
13 (10.2)
|
65 (51.1)
|
0.38
|
0.81 (0.53–1.25)
|
|
Endometrioid
|
82
|
44 (53.6)
|
29 (35.4)
|
9 (11.0)
|
38 (46.4)
|
0.13
|
0.67 (0.41–1.11)
|
|
Mucinous
|
42
|
23 (54.8)
|
16 (38.1)
|
3 (7.1)
|
19 (45.2)
|
0.24
|
0.64 (0.33–1.24)
|
|
Clear Cell
|
13
|
4 (30.8)
|
8 (61.5)
|
1 (7.7)
|
9 (69.2)
|
0.40
|
1.75 (0.52–5.83)
|
|
Adenocarcinoma
|
49
|
24 (49.0)
|
21 (42.8)
|
4 (8.2)
|
25 (51.0)
|
0.53
|
0.81 (0.44–1.49)
|
|
Borderline
|
15
|
6 (40.0)
|
8 (53.3)
|
1 (6.7)
|
9 (60.0)
|
1.00
|
1.16 (0.40–3.37)
|
|
Benign
|
62
|
39 (62.9)
|
19 (30.6)
|
4 (6.4)
|
23 (37.0)
|
0.007
|
0.46 (0.26–0.81)
|
- Allele 1 corresponds to the single copy allele, allele 2 corresponds to the duplication allele.
-
aFisher's exact test (two-sided) for the combined 12/22 genotype frequency using the 11 homozygotes as reference.
-
bThe odds ratio (OR) and 95% confidence intervals (CI) are shown in parentheses.
